A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Advanced Breast Cancer
This randomized phase III trial studies exemestane and entinostat to see how well they work
compared to exemestane alone in treating patients with hormone receptor-positive breast
cancer that has spread to nearby tissue or lymph nodes or another place in the body. Estrogen
can cause the growth of breast cancer cells. Endocrine therapy using exemestane may fight
breast cancer by lowering the amount of estrogen the body makes. Entinostat may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet
known whether exemestane is more effective with or without entinostat in treating breast
Lebanon,Manchester,Nashua,St. Johnsbury, VT
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.